
Search
Filter Results
Displaying 71–80 of 624 for “retinal diseases”
-
Aug 16, 2019
Foundation Fighting Blindness Investing Nearly $6.5 Million in New Grants
The newly funded research efforts include several therapies that have strong potential to treat a wide range of inherited retinal diseases.
-
Scientific Grants and Awards Programs
The Grants and Awards Programs of the Foundation Fighting Blindness support basic, laboratory-based early translational, clinical studies and pre-clinical research applicable to a broad range of retinal degenerative diseases.
-
Nov 14, 2024
Strengthening research in retinal disease with record-breaking $19.8 million investment in innovative projects targeting vision loss worldwide.
-
Apr 28, 2023
Dr. Tucker is leading the development of GMP facilities for manufacturing clinical grade retinal therapies
-
Jul 5, 2018
Retinal Regeneration: Releasing Your Inner Salamander
Many research groups from around the world are investigating ways to create new photoreceptors from stem cells for transplantation into the retina for vision restoration.
-
Oct 18, 2024
MicroRNA Breakthroughs: Paving the Way for Vision Restoration
Researchers funded by the Foundation Fighting Blindness are developing microRNA-based therapies for inherited retinal diseases, building on recent Nobel Prize-winning discoveries.
-
Aug 6, 2018
FFB Funding More than $2 Million in New Research
Seventy scientists submitted requests for funding.
-
Jun 21, 2023
Dan Day - Making a Difference Now and for Future Generations
“Because I have seen such tremendous progress over the years, and I want that progress to continue until the day when we have cures for all retinal diseases, it is important to me that the Foundation be part of my lasting legacy.”
-
Quarterly vision webinars providing key information impacting our community.
-
Apr 10, 2025
The partnership will formalize an ongoing commitment by both companies to accelerate the development of treatments and cures for retinal diseases, while prioritizing a patient-centric approach.